ENTEROGERMINA ® Spore by Bacillus Clausii

ENTEROGERMINA ® is a drug based on spores of Bacillus Cluasii resistant poliantibiotic

THERAPEUTIC GROUP: Antidiarrheal - Antidiarrheal microorganisms.

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Directions ENTEROGERMINA ® Spore by Bacillus Clausii

ENTEROGERMINA ® is a medicine used in the prophylaxis and treatment of intestinal dismicrobism. The effectiveness of ENTEROGERMINA ® in restoring the correct bacterial flora also makes it useful in the course of antibiotic therapies or gastro-enteric diseases of infectious origin with associated symptoms.

Mode of action ENTEROGERMINA ® Spore by Bacillus Clausii

The microorganisms contained in ENTEROGERMINA ® are part of the common constitution of intestinal bacterial flora. The spore form, particularly resistant to environmental adversities, allows the Bacillus Clausii to survive the gastric acid environment unscathed, reaching the intestinal lumen, where thanks to a favorable environment it can originate again the vegetative form.

The benefits of ENTEROGERMINA ® in terms of restoring the resident bacterial flora are guaranteed both by the ability to form new vital colonies, by rebalancing the present population, and by the ability to increase the production of B vitamins and active metabolites useful to sustain the vitality of the intestinal mucosa. At the same time, ENTEROGERMINA ® has a bactericidal action against any pathogenic component, both indirect (competition for sites of adhesion to the intestinal mucosa) and direct (secretion of active substances with direct or indirect bactericidal action).

Furthermore, the polyantibiotic resistance allows B.Clausii to be successfully used also during antibiotic therapy, without being affected by the cytotoxic effects induced by the drug.

The antidiarrheal action of the ENEROGERMINA ® seems to be carried out both through the bactericidal action against pathogens, and through the ability of its metabolites to reconstitute the integrity of the intestinal mucosa.

Studies carried out and clinical efficacy

BACILLUS CLAUSII DURING THE ERADICATION TREATMENT OF H.PYLORI

The eradication of H.Pylori requires an important antibiotic therapy, which in most cases is accompanied by the onset of side effects - such as nausea, diarrhea and abdominal pain - partly responsible for the suspension of therapy. The concurrent intake of B.Clausii seems to effectively reduce this annoying symptomatology, also improving the response to antibiotic therapy.

2. ENTEROGERMINE AND IMMUNOMODULATION

It is known that the intestine represents a very important immune organ, so changes in its state of health can affect the patient's overall immunological condition. This Italian study, in fact, shows how the prolonged administration of B.Clausii spores can vary the immunological picture in allergic individuals, guaranteeing an immunomodulatory and regulatory action.

3.BACILLUS CLAUSII NOT JUST A PROBIOTIC

Experimental evidence suggests that the activity of B.Clausii is not only linked to its probiotic action, but also to various other molecular mechanisms still to be clarified. An in vitro study has in fact observed how this microorganism, in contact with cells of the intestinal mucosa, can guarantee a modulation of the gene expression and precisely of about 158 genes. These mechanisms could underlie the direct effects on the intestinal mucosa.

Method of use and dosage

ENTEROGERMINA ® vial or capsules of 2 billion spores of Bacillus Clausii resistant poliantibiotico: we recommend taking two / three capsules or vials a day taken at regular intervals of 4 hours, until the improvement of symptoms. The vials can be diluted in a beverage of your choice.

The dosage for children should be quantitatively halved compared to the adult.

Warnings ENTEROGERMINA ® Spore by Bacillus Clausii

There are no special precautions regarding the use of ENTEROGERMINA ®

The high safety profile and the absence of systemic absorption with relative metabolism, allows its use also in patients suffering from hepatic and renal pathologies.

The presence of corpuscles in the contents of the vial is not necessarily a sign of sophistication of the product, but must be traced (when the conservation rules are respected) to the presence of spore aggregates; therefore, before taking the medicine it would be advisable to shake it.

ENTEROGERMINA ® absolutely does not alter the normal ability to drive or use machinery.

PREGNANCY AND BREASTFEEDING

ENTEROGERMINA ® is safe and well tolerated even when taken during pregnancy.

Despite the excellent safety profile, it would still be advisable and preferable to warn your doctor before taking any type of medicine.

Interactions

Clinically relevant interactions between ENTEROGERMINA ® of other active ingredients are currently unknown.

Resistance poliantibiotic allows its use also in the course of antibiotic and pharmacological therapy in general (in this case it would be useful to take ENTEROGERMINA ® between antibiotics).

Contraindications ENTEROGERMINA ® Spore by Bacillus Clausii

ENTEROGERMINA ® is contraindicated in patients with established hypersensitivity to one of its components

Undesirable effects - Side effects

The scientific literature seems to agree somewhat on the assumption of ENTEROGERMINA ® being safe and well tolerated given the absence of clinically relevant side effects.

However, from the post-marketing experience emerges, in rare cases, the appearance of flatulence and abdominal pain following the chronic intake of probiotic drugs.